esional evaluation of high-risk patients with neoatherosclerosis treated with rosuvastatin and eicosapentaenoic acid using OCT and NIRS IVUS
Not Applicable
- Conditions
- ischemic heart disease
- Registration Number
- JPRN-UMIN000033335
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients taking omega 3 fatty acid before randomization 2 Patients allergic to rosuvastatin or eicosapentaenoic acid 3 Patients with a history of hemorrhagic stroke 4 Patients taking anti cancer agent 5 Patients undergoing LDL apheresis 6 Patients with severe liver disease or severe kidney disease 7 Patients who conflict with any of the warnings or contraindications listed in the domestic package insert of rosuvastatin 8 Patients who conflict with any of the warnings or contraindications listed in the domestic package insert of eicosapentaenoic acid 9 Patients perfomed PCI with restenosis of target lesion 10 Pregnant women or patients with possibilty of Pregnancy or nursing woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method lipid index
- Secondary Outcome Measures
Name Time Method 1 Major adverse cardiac event 2 follow up OCT data Minimum lumen area, average neointimal thickness, lipid arc, lipid length, TCFA, macrophage grade 3 NIRS IVUS LCBI 4mm, plaque volume